Anti-VGFR3/ FLT-4/ FLT4 monoclonal antibody
Anti-VGFR3/ FLT-4/ FLT4 antibody for FACS & in-vivo assay
Go to FLT-4/FLT4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T07303-Ab-1/ GM-Tg-hg-T07303-Ab-2 | Anti-Human FLT-4/FLT4 monoclonal antibody | Human |
GM-Tg-rg-T07303-Ab-1/ GM-Tg-rg-T07303-Ab-2 | Anti-Rat FLT-4/FLT4 monoclonal antibody | Rat |
GM-Tg-mg-T07303-Ab-1/ GM-Tg-mg-T07303-Ab-2 | Anti-Mouse FLT-4/FLT4 monoclonal antibody | Mouse |
GM-Tg-cynog-T07303-Ab-1/ GM-Tg-cynog-T07303-Ab-2 | Anti-Cynomolgus/ Rhesus macaque FLT-4/FLT4 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T07303-Ab-1/ GM-Tg-felg-T07303-Ab-2 | Anti-Feline FLT-4/FLT4 monoclonal antibody | Feline |
GM-Tg-cang-T07303-Ab-1/ GM-Tg-cang-T07303-Ab-2 | Anti-Canine FLT-4/FLT4 monoclonal antibody | Canine |
GM-Tg-bovg-T07303-Ab-1/ GM-Tg-bovg-T07303-Ab-2 | Anti-Bovine FLT-4/FLT4 monoclonal antibody | Bovine |
GM-Tg-equg-T07303-Ab-1/ GM-Tg-equg-T07303-Ab-2 | Anti-Equine FLT-4/FLT4 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T07303-Ab-1/ GM-Tg-hg-T07303-Ab-2; GM-Tg-rg-T07303-Ab-1/ GM-Tg-rg-T07303-Ab-2; GM-Tg-mg-T07303-Ab-1/ GM-Tg-mg-T07303-Ab-2; GM-Tg-cynog-T07303-Ab-1/ GM-Tg-cynog-T07303-Ab-2; GM-Tg-felg-T07303-Ab-1/ GM-Tg-felg-T07303-Ab-2; GM-Tg-cang-T07303-Ab-1/ GM-Tg-cang-T07303-Ab-2; GM-Tg-bovg-T07303-Ab-1/ GM-Tg-bovg-T07303-Ab-2; GM-Tg-equg-T07303-Ab-1/ GM-Tg-equg-T07303-Ab-2 |
Products Name | Anti-FLT-4/FLT4 monoclonal antibody |
Format | mab |
Target Name | FLT-4 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-FLT-4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species VGFR3/ FLT-4/ FLT4 VLP (virus-like particle) (Products Developing) |
Cytokine | GM-Tg-g-T07303-Ag-1 | fms-related tyrosine kinase 4 (FLT4) protein |
Target information
Target ID | GM-T07303 |
Target Name | FLT-4 |
Gene ID | 2324,14257,114110,716412,481464,101094727,338031,100066773 |
Gene Symbol and Synonyms | CHTD7,Chy,FLT-4,FLT4,FLT41,LMPH1A,LMPHM1,PCL,VEGFR-3,VEGFR3 |
Uniprot Accession | P35916,Q91ZT1 |
Uniprot Entry Name | VGFR3_HUMAN,VGFR3_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Cytokine Target |
Disease | Cancer |
Gene Ensembl | ENSG00000037280 |
Target Classification | Kinase, Tumor-associated antigen (TAA) |
The target: FLT-4, gene name: FLT4, also named as FLT-41, LMPH1A, PCL, VEGFR-3, VEGFR3, FLT4. This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.